Dr. Morris on rPFS as an Endpoint in Clinical Trials

Video

Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the use of radiographic progression-free survival as an endpoint in prostate cancer clinical trials.

Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the use of radiographic progression-free survival (rPFS) as an endpoint in prostate cancer clinical trials.

Traditionally, Morris says, it had to be demonstrated that patients lived longer (overall survival) or better (skeletal-related event prevention) as a result of treatment. These endpoints take substantial time to evaluate. Morris also notes that it is difficult to determine if benefit is a result of the drug being tested or another therapy given after the conclusion of a clinical trial.

The challenge of finding earlier endpoints that are closely associated with overall survival may have been answered by rPFS, which is a standardized definition of when a patient has progressed on a trial. Researchers and physicians are setting the stage for rPFS to be established as an interim endpoint in this disease as it is so closely associated with a "hard" clinical endpoint.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD